Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood
<b>Background</b>: Circulating tumour DNA (ctDNA) has emerged as a promising biomarker for monitoring non-small-cell lung cancer (NSCLC). This has enabled the monitoring of clinically actionable mutations over the course of therapy. <b>Case presentation:</b> We present the ca...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Reports |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2571-841X/3/4/33 |
| _version_ | 1797548877784547328 |
|---|---|
| author | Arutha Kulasinghe James Monkman Mark Nalder Connor O’Leary Rahul Ladwa Ken O’Byrne |
| author_facet | Arutha Kulasinghe James Monkman Mark Nalder Connor O’Leary Rahul Ladwa Ken O’Byrne |
| author_sort | Arutha Kulasinghe |
| collection | DOAJ |
| description | <b>Background</b>: Circulating tumour DNA (ctDNA) has emerged as a promising biomarker for monitoring non-small-cell lung cancer (NSCLC). This has enabled the monitoring of clinically actionable mutations over the course of therapy. <b>Case presentation:</b> We present the case of a 74-year-old female who was treated with EGFR inhibitors for NSCLC which later transformed to SCLC. The kinetics of ctDNA was monitored by measuring the EGFR Exon 19 mutant L747–A750 > P and PIK3CA E545K over the course of therapy. Stabilisation of the PIK3CA mutation was found in response to therapy, however there appeared to be increasing levels of the EGFR mutant, potentially reflective of untreated EGFR-driven disease. <b>Conclusion:</b> The key finding described here, revealed by mutational tracking of mutations from the blood, is that clinically actionable mutations are assessable and may demonstrate clinical utility in measuring disease burden, multiple clones and progression non-invasively for lung cancer. |
| first_indexed | 2024-03-10T15:06:03Z |
| format | Article |
| id | doaj.art-65669ac6612e4e82be60f309414e2b30 |
| institution | Directory Open Access Journal |
| issn | 2571-841X |
| language | English |
| last_indexed | 2024-03-10T15:06:03Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Reports |
| spelling | doaj.art-65669ac6612e4e82be60f309414e2b302023-11-20T19:44:09ZengMDPI AGReports2571-841X2020-11-01343310.3390/reports3040033Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the BloodArutha Kulasinghe0James Monkman1Mark Nalder2Connor O’Leary3Rahul Ladwa4Ken O’Byrne5The School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, 37 Kent Street, Woolloongabba, QLD 4102, AustraliaThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, 37 Kent Street, Woolloongabba, QLD 4102, AustraliaPrincess Alexandra Hospital, Brisbane, QLD 4102, AustraliaThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, 37 Kent Street, Woolloongabba, QLD 4102, AustraliaPrincess Alexandra Hospital, Brisbane, QLD 4102, AustraliaThe School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, 37 Kent Street, Woolloongabba, QLD 4102, Australia<b>Background</b>: Circulating tumour DNA (ctDNA) has emerged as a promising biomarker for monitoring non-small-cell lung cancer (NSCLC). This has enabled the monitoring of clinically actionable mutations over the course of therapy. <b>Case presentation:</b> We present the case of a 74-year-old female who was treated with EGFR inhibitors for NSCLC which later transformed to SCLC. The kinetics of ctDNA was monitored by measuring the EGFR Exon 19 mutant L747–A750 > P and PIK3CA E545K over the course of therapy. Stabilisation of the PIK3CA mutation was found in response to therapy, however there appeared to be increasing levels of the EGFR mutant, potentially reflective of untreated EGFR-driven disease. <b>Conclusion:</b> The key finding described here, revealed by mutational tracking of mutations from the blood, is that clinically actionable mutations are assessable and may demonstrate clinical utility in measuring disease burden, multiple clones and progression non-invasively for lung cancer.https://www.mdpi.com/2571-841X/3/4/33circulating tumour dnanon-small-cell lung cancermutations |
| spellingShingle | Arutha Kulasinghe James Monkman Mark Nalder Connor O’Leary Rahul Ladwa Ken O’Byrne Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood Reports circulating tumour dna non-small-cell lung cancer mutations |
| title | Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood |
| title_full | Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood |
| title_fullStr | Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood |
| title_full_unstemmed | Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood |
| title_short | Transformation or Progression from Adenocarcinoma to Small Cell Lung Cancer Detected by Serially Tracking Mutations in the Blood |
| title_sort | transformation or progression from adenocarcinoma to small cell lung cancer detected by serially tracking mutations in the blood |
| topic | circulating tumour dna non-small-cell lung cancer mutations |
| url | https://www.mdpi.com/2571-841X/3/4/33 |
| work_keys_str_mv | AT aruthakulasinghe transformationorprogressionfromadenocarcinomatosmallcelllungcancerdetectedbyseriallytrackingmutationsintheblood AT jamesmonkman transformationorprogressionfromadenocarcinomatosmallcelllungcancerdetectedbyseriallytrackingmutationsintheblood AT marknalder transformationorprogressionfromadenocarcinomatosmallcelllungcancerdetectedbyseriallytrackingmutationsintheblood AT connoroleary transformationorprogressionfromadenocarcinomatosmallcelllungcancerdetectedbyseriallytrackingmutationsintheblood AT rahulladwa transformationorprogressionfromadenocarcinomatosmallcelllungcancerdetectedbyseriallytrackingmutationsintheblood AT kenobyrne transformationorprogressionfromadenocarcinomatosmallcelllungcancerdetectedbyseriallytrackingmutationsintheblood |